Bile acids as novel pharmacological agents: The interplay between gene polymorphisms, epigenetic factors and drug response

Current Pharmaceutical Design

Volumn 23, Issue 1, 2017, Pages 187-215

  Pavlović, Nebojša ^a   Stanimirov, Bojan ^a   Mikov, Momir ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Bile acids; Drug development; Epigenetics; Farnesoid X receptor; Nuclear receptors; Pharmacogenetics; Polymorphisms; TGR5

Indexed keywords

BILE ACID; BRG1 PROTEIN; BRM PROTEIN; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTONE DEACETYLASE; LIGAND; PREGNANE X RECEPTOR; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN SWI; TRANSCRIPTION FACTOR SNF; CELL RECEPTOR;

BILE ACID METABOLISM; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG MECHANISM; DRUG RESPONSE; EPIGENETICS; GENETIC VARIATION; GLUCOSE HOMEOSTASIS; HISTONE METHYLATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LIPOPROTEIN METABOLISM; MOLECULAR BIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TISSUE DISTRIBUTION; TREATMENT OUTCOME; XENOBIOTIC METABOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; DRUG EFFECTS; GENETIC EPIGENESIS; GENETIC POLYMORPHISM; GENETICS; LIVER DISEASE; METABOLISM; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ANIMALS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; DIABETES MELLITUS, TYPE 2; EPIGENESIS, GENETIC; HUMANS; LIVER DISEASES; NEOPLASMS; OBESITY; POLYMORPHISM, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 85013888795     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666161006161409     Document Type: Review

References (365)

1. Copple BL, Li T. Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res 2016; 104: 9-21.
2. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap-bile acids in metabolic control. Nat Rev Endocrinol 2014; 10: 488-98.
3. Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 2014; 11: 55-67.
4. Mullard A. 2015 FDA drug approvals. Nat Rev Drug Discov 2016; 15: 73-76.
5. Stankov K, Stanimirov B, Mikov M. Pharmacogenomic determinants of response to cardiovascular drugs. Med Pregl 2015; 68: 259-65.
6. De Mattia E, Dreussi E, Cecchin E, et al. Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects? Pharmacogenomics 2013; 14: 2035-54.
7. Cascorbi I. Overlapping effects of genetic variation and epigenetics on drug response: Challenges of pharmacoepigenomics. Pharmacogenomics 2013; 14: 1807-9.
8. Mendiratta S, Jain S, Maini J, et al. Pharmacoepigenomics: an interplay of epigenetic modulation of drug response and modulation of the epigenome by drugs. Curr Pharm Des 2014; 20: 1819-30.
9. Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol Cell 2007; 27: 691-700.
10. Otte K, Kranz H, Kober I, et al. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol 2003; 23: 864-72.
11. Modica S, Moschetta A. Nuclear bile acid receptor FXR as pharmacological target: are we there yet? FEBS Lett 2006; 580: 5492-9.
12. Kemper JK. Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and posttranslational modifications. Biochim Biophys Acta 2011; 1812: 842-50.
13. Huber RM, Murphy K, Miao B, et al. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002; 290: 35-43.
14. Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem 2003; 278: 104-10.
15. Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal 2010; 8: e005.
16. Stanimirov B, Stankov K, Mikov M. Pleiotropic functions of bile acids mediated by the farnesoid X receptor. Acta Gastroenterol Belg 2012; 75: 389-98.
17. Baptissart M, Vega A, Martinot E, et al. Farnesoid X receptor alpha: a molecular link between bile acids and steroid signaling? Cell Mol Life Sci 2013; 70: 4511-26.
18. Fiorucci S, Rizzo G, Donini A, et al. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13: 298-309.
19. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-91.
20. Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 2005; 48: 5383-403.
21. Lee FY, Lee H, Hubbert ML, et al. FXR, a multipurpose nuclear receptor. Trends Biochem Sci 2006; 31: 572-80.
22. Gadaleta RM, Magnani L. Nuclear receptors and chromatin: an inducible couple. J Mol Endocrinol 2014; 52: R137-49.
23. Mi LZ, Devarakonda S, Harp JM, et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell 2003; 11: 1093-100.
24. Forman BM, Goode E, Chen J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995; 81: 687-93.
25. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-5.
26. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-8.
27. Rizzo G, Renga B, Mencarelli A, et al. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 289-303.
28. Mazuy C, Helleboid A, Staels B, et al. Nuclear bile acid signaling through the farnesoid X receptor. Cell Mol Life Sci 2015; 72: 1631-50.
29. Pavlovic N, Stankov K, Mikov M. Probiotics-interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol 2012; 168: 1880-95.
30. Kuhajda K, Kevresan S, Kandrac J, et al. Chemical and metabolic transformations of selected bile acids. Eur J Drug Metab Pharmacokinet 2006; 31: 179-235.
31. Beuers U, Trauner M, Jansen P, et al. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 2015; 62: S25-37.
32. Sepe V, Distrutti E, Fiorucci S, et al. Farnesoid X receptor modulators (2011-2014): a patent review. Expert Opin Ther Pat 2015; 25: 885-96.
33. Gioiello A, Cerra B, Mostarda S, et al. Bile acid derivatives as ligands of the farnesoid x receptor: Molecular determinants for bile acid binding and receptor modulation. Curr Top Med Chem 2014; 14: 2159-74.
34. Katona BW, Cummins CL, Ferguson AD, et al. Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids. J Med Chem 2007; 50: 6048-58.
35. Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009; 50: 2340-57.
36. Carotti A, Marinozzi M, Custodi C, et al. Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands. Curr Top Med Chem 2014; 14: 2129-42.
37. Crawley ML. Farnesoid X receptor modulators: a patent review. Expert Opin Ther Pat 2010; 20: 1047-57.
38. Gege C, Kinzel O, Steeneck C, et al. Knocking on FXR's door: the "hammerhead"-structure series of FXR agonists-amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr Top Med Chem 2014; 14: 2143-58.
39. Hambruch E, Miyazaki-Anzai S, Hahn U, et al. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic lowdensity lipoprotein receptor (-/-) mice. J Pharmacol Exp Ther 2012; 343: 556-67.
40. Nicolaou KC, Evans RM, Roecker AJ, et al. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org Biomol Chem 2003; 1: 908-20.
41. Fang S, Suh JM, Reilly SM, et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 2015; 21: 159-65.
42. Flatt B, Martin R, Wang TL et al. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J Med Chem 2009; 52: 904-7.
43. Evans MJ, Mahaney PE, Borges-Marcucci L, et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 2009; 296: G543-52.
44. Liu X, Xue R, Ji L, et al. Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction. Biochem Biophys Res Commun 2014; 450: 117-23.
45. Wu W, Zhu B, Peng X, et al. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 2014; 443: 68-73.
46. Pellicciari R, Fiorucci S, Camaioni E et al. 6alpha-ethylchenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45: 3569-72.
47. Di Leva FS, Festa C, D'Amore C, et al. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. J Med Chem 2013; 56: 4701-17.
48. Fiorucci S, Clerici C, Antonelli E, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005; 313: 604-12.
49. Fiorucci S, Antonelli E, Rizzo G, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127: 1497-512.
50. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-97.
51. Maneschi E, Vignozzi L, Morelli A, et al. FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol 2013; 218: 215-31.
52. Verbeke L, Farre R, Trebicka J, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014; 59: 2286-98.
53. Verbeke L, Farre R, Verbinnen B et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 2015; 185: 409-19.
54. Walters JR, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015; 41: 54-64.
55. Ho PP, Steinman L. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2016; 113: 1600-5.
56. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-82.
57. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385: 956-65.
58. Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148: 751-61.
59. Alemi F, Kwon E, Poole DP, et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J Clin Invest 2013; 123: 1513-30.
60. D'Amore C, Di Leva FS, Sepe V, et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J Med Chem 2014; 57: 937-54.
61. Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis: facts and fiction. Hepatology 2014; 60: 399-407.
62. Stanimirov B, Stankov K, Mikov M. Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseases. Hepatobiliary Pancreat Dis Int 2015; 14: 18-33.
63. Owsley E, Chiang JY. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem Biophys Res Commun 2003; 304: 191-5.
64. Urizar NL, Liverman AB, Dodds DT, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296: 1703-6.
65. Cui J, Huang L, Zhao A, et al. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 2003; 278: 10214-20.
66. Guan B, Li H, Yang Z, et al. Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts. Cancer 2013; 119: 1321-9.
67. Scholtes C, Andre P, Trepo C, et al. Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial. Therapie 2012; 67: 423-7.
68. Jiang C, Xie C, Lv Y, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015; 6: 10166.
69. Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim Biophys Acta 2011; 1812: 893-908.
70. Kir S, Zhang Y, Gerard RD, et al. Nuclear receptors HNF4alpha and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem 2012; 287: 41334-41.
71. Kliewer SA, Mangelsdorf DJ. Bile Acids as Hormones: The FXRFGF15/ 19 Pathway. Dig Dis 2015; 33: 327-31.
72. Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med 2014; 37: 57-76.
73. Chen J, Zhao KN, Chen C. The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis. Ann Transl Med 2014; 2: 7.
74. Mackenzie PI, Hu DG, Gardner-Stephen DA. The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligandactivated transcription factors. Drug Metab Rev 2010; 42: 99-109.
75. Marzolini C, Tirona RG, Gervasini G, et al. A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol Endocrinol 2007; 21: 1769-80.
76. van Mil SWC, Milona A, Dixon PH, et al. Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 2007; 133: 507-16.
77. Hirobe-Jahn S, Harsch S, Renner O, et al. Association of FXR gene variants with cholelithiasis. Clin Res Hepatol Gastroenterol 2015; 39: 68-79.
78. Schoenfield LJ, Lachin JM. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann Intern Med 1981; 95: 257-82.
79. Lambert G, Amar MJ, Guo G, et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003; 278: 2563-70.
80. Gautier T, de Haan W, Grober J, et al. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. J Lipid Res 2013; 54: 2195-205.
81. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-18.
82. Pineda Torra I, Claudel T, Duval C, et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003; 17: 259-72.
83. Pan X, Zhang Y, Wang L, et al. Diurnal regulation of MTP and plasma triglyceride by CLOCK is mediated by SHP. Cell Metab 2010; 12: 174-86.
84. Jiao Y, Lu Y, Li XY. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis. Acta Pharmacol Sin 2015; 36: 44-50.
85. Koutsounas I, Theocharis S, Delladetsima I, et al. Farnesoid x receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. Expert Opin Drug Metab Toxicol 2015; 11: 523-32.
86. Hu M, Lui SSH, Tam LS, et al.The farnesoid X receptor-1G>T polymorphism influences the lipid response to rosuvastatin. J Lipid Res 2012; 53: 1384-9.
87. van den Berg SW, Dolle ME, Imholz S, et al. Genetic variations in regulatory pathways of fatty acid and glucose metabolism are associated with obesity phenotypes: a population-based cohort study. Int J Obes (Lond) 2009; 33: 1143-52.
88. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr Diab Rep 2011; 11: 160-6.
89. Ma K, Saha PK, Chan L, et al. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-9.
90. Dufer M, Horth K, Krippeit-Drews P, et al. The significance of the nuclear farnesoid X receptor (FXR) in beta cell function. Islets 2012; 4: 333-8.
91. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of beta Klotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282: 26687-95.
92. Popescu IR, Helleboid-Chapman A, Lucas A, et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett 2010; 584: 2845-51.
93. Heni M, Wagner R, Ketterer C, et al. Genetic variation in NR1H4 encoding the bile acid receptor FXR determines fasting glucose and free fatty acid levels in humans. J Clin Endocrinol Metab 2013; 98: E1224-9.
94. Gadaleta RM, van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-72.
95. Stojancevic M, Stankov K, Mikov M. The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol 2012; 26: 631-7.
96. Nijmeijer RM, Gadaleta RM, van Mil SWC, et al. Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One 2011; 6: e23745.
97. Attinkara R, Mwinyi J, Truninger K, et al. Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease. BMC Res Notes 2012; 5: 461.
98. Lutz P, Berger C, Langhans B, et al. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig Liver Dis 2014; 46: 1047-50.
99. Suchy FJ, Ananthanarayanan M. Bile Acid Hepatotoxicity: Epigenetics Comes to the Rescue. Hepatology 2015; 62: 22-24.
100. Zou A, Lehn S, Magee N, et al. New Insights into Orphan Nuclear Receptor SHP in Liver Cancer. Nucl Receptor Res 2015; 2.
101. Miao J, Fang S, Lee J, et al. Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol Cell Biol 2009; 29: 6170-81.
102. Fang S, Miao J, Xiang L, et al. Coordinated recruitment of histone methyltransferase G9a and other chromatin-modifying enzymes in SHP-mediated regulation of hepatic bile acid metabolism. Mol Cell Biol 2007; 27: 1407-24.
103. Smith Z, Ryerson D, Kemper JK. Epigenomic regulation of bile acid metabolism: emerging role of transcriptional cofactors. Mol Cell Endocrinol 2013; 368: 59-70.
104. Kemper JK, Kim H, Miao J, et al. Role of an mSin3A-Swi/Snf chromatin remodeling complex in the feedback repression of bile acid biosynthesis by SHP. Mol Cell Biol 2004; 24: 7707-19.
105. Kim HS, Shen Q, Nam SW. Histone deacetylases and their regulatory MicroRNAs in hepatocarcinogenesis. J Korean Med Sci 2015; 30: 1375-80.
106. Menzies KJ, Zhang H, Katsyuba E, et al. Protein acetylation in metabolism-metabolites and cofactors. Nat Rev Endocrinol 2016; 12: 43-60.
107. Gobinet J, Carascossa S, Cavailles V, et al. SHP represses transcriptional activity via recruitment of histone deacetylases. Biochemistry 2005; 44: 6312-20.
108. Mitro N, Godio C, De Fabiani E, et al. Insights in the regulation of cholesterol 7alpha-hydroxylase gene reveal a target for modulating bile acid synthesis. Hepatology 2007; 46: 885-97.
109. Su H, Ma C, Liu J, et al. Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol 2012; 303: G1245-53.
110. Liu X, Zhang X, Ji L, et al. Farnesoid X receptor associates with beta-catenin and inhibits its activity in hepatocellular carcinoma. Oncotarget 2015; 6: 4226-38.
111. Deuschle U, Birkel M, Hambruch E, et al. The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidinerich glycoprotein. Int J Cancer 2015; 136: 2693-704.
112. Wang X, Jiang B, Zhang Y. Gankyrin regulates cell signaling network. Tumour Biol 2016; 37(5): 5675-82.
113. Jiang Y, Iakova P, Jin J, et al. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. Hepatology 2013; 57: 1098-106.
114. Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med 2011; 43: 198-211.
115. Bosch-Presegue L, Vaquero A. Sirtuin-dependent epigenetic regulation in the maintenance of genome integrity. FEBS J 2015; 282: 1745-67.
116. Kemper JK, Xiao Z, Ponugoti B, et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 2009; 10: 392-404.
117. Fang S, Tsang S, Jones R, et al. The p300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP. J Biol Chem 2008; 283: 35086-95.
118. Purushotham A, Xu Q, Lu J, et al. Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1alpha/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice. Mol Cell Biol 2012; 32: 1226-36.
119. Fu ZD, Cui JY, Klaassen CD. The role of Sirt1 in bile acid regulation during calorie restriction in mice. PLoS One 2015; 10: e0138307.
120. Diaz-Gerevini GT, Repossi G, Dain A, et al. Beneficial action of resveratrol: How and why? Nutrition 2016; 32: 174-8.
121. Traboulsi H, Davoli S, Catez P, et al. Dynamic partnership between TFIIH, PGC-1alpha and SIRT1 is impaired in trichothiodystrophy. PLoS Genet 2014; 10: e1004732.
122. Lee J, Padhye A, Sharma A, et al. A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition. J Biol Chem 2010; 285: 12604-11.
123. Kazgan N, Metukuri MR, Purushotham A, et al. Intestine-specific deletion of SIRT1 in mice impairs DCoH2-HNF-1alpha-FXR signaling and alters systemic bile acid homeostasis. Gastroenterology 2014; 146: 1006-16.
124. Quinones M, Al-Massadi O, Ferno J, et al. Cross-talk between SIRT1 and endocrine factors: effects on energy homeostasis. Mol Cell Endocrinol 2014; 397: 42-50.
125. Cao Y, Jiang X, Ma H, Wang Y, Xue P, Liu Y. SIRT1 and insulin resistance. J Diabetes Complications 2016; 30: 178-83.
126. Mellini P, Valente S, Mai A. Sirtuin modulators: an updated patent review (2012-2014). Expert Opin Ther Pat 2015; 25: 5-15.
127. Garcia-Rodriguez JL, Barbier-Torres L, Fernandez-Alvarez S, et al. SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. Hepatology 2014; 59: 1972-83.
128. Huang W, Ma K, Zhang J, et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006; 312: 233-6.
129. Dancy BM, Cole PA. Protein lysine acetylation by p300/CBP. Chem Rev 2015; 115: 2419-52.
130. Bricambert J, Miranda J, Benhamed F, et al. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest 2010; 120: 4316-31.
131. Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. Science Adv 2015; 1: e1500447.
132. Kadam S, Emerson BM. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 2003; 11: 377-89.
133. Kanamaluru D, Xiao Z, Fang S, et al. Arginine methylation by PRMT5 at a naturally occurring mutation site is critical for liver metabolic regulation by small heterodimer partner. Mol Cell Biol 2011; 31: 1540-50.
134. Du J, Johnson LM, Jacobsen SE, et al. DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol 2015; 16: 519-32.
135. Shankar SR, Bahirvani AG, Rao VK, et al. G9a, a multipotent regulator of gene expression. Epigenetics 2013; 8: 16-22.
136. Boulias K, Talianidis I. Functional role of G9a-induced histone methylation in small heterodimer partner-mediated transcriptional repression. Nucleic Acids Res 2004; 32: 6096-103.
137. Li T, Chanda D, Zhang Y, et al. Glucose stimulates cholesterol 7α-hydroxylase gene transcription in human hepatocytes. J Lipid Res 2010; 51: 832-42.
138. Pradhan S, Chin HG, Esteve PO, Jacobsen SE. SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 2009; 4: 383-7.
139. Liu X, Wang D, Zhao Y, et al. Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proc Natl Acad Sci USA 2011; 108: 1925-30.
140. Niwa H, Handa N, Tomabechi Y, et al. Structures of histone methyltransferase SET7/9 in complexes with adenosylmethionine derivatives. Acta Crystallogr D Biol Crystallogr 2013; 69: 595-602.
141. Balasubramaniyan N, Ananthanarayanan M, Suchy FJ. Direct methylation of FXR by Set7/9, a lysine methyltransferase, regulates the expression of FXR target genes. Am J Physiol-Gastrointestinal Liver Physiol 2012; 302: G937-47.
142. Sheen-Chen SM, Lin CR, Chen KH, et al. Epigenetic histone methylation regulates transforming growth factor beta-1 expression following bile duct ligation in rats. J Gastroenterol 2014; 49: 1285-97.
143. Rudolph T, Beuch S, Reuter G. Lysine-specific histone demethylase LSD1 and the dynamic control of chromatin. Biol Chem 2013; 394: 1019-28.
144. Ouyang H, Qin Y, Liu Y, et al. Prox1 directly interacts with LSD1 and recruits the LSD1/NuRD complex to epigenetically co-repress CYP7A1 transcription. PLoS One 2013; 8: e62192.
145. Kim YC, Fang S, Byun S, et al. Farnesoid X receptor-induced lysine-specific histone demethylase reduces hepatic bile acid levels and protects the liver against bile acid toxicity. Hepatology 2015; 62: 220-31.
146. Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why. Mol Cell 2009; 33: 1-13.
147. Kwak YT, Guo J, Prajapati S, et al. Methylation of SPT5 regulates its interaction with RNA polymerase II and transcriptional elongation properties. Mol Cell 2003; 11: 1055-66.
148. Dacwag CS, Ohkawa Y, Pal S, et al. The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATP-dependent chromatin remodeling. Mol Cell Biol 2007; 27: 384-94.
149. Jansson M, Durant ST, Cho EC, et al. Arginine methylation regulates the p53 response. Nat Cell Biol 2008; 10: 1431-9.
150. Rizzo G, Renga B, Antonelli E, et al. The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol 2005; 68: 551-8.
151. Xie Y, Ke S, Ouyang N, et al. Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J Biol Chem 2009; 284: 9199-205.
152. Ananthanarayanan M, Li S, Balasubramaniyan N, et al. Liganddependent activation of the farnesoid X-receptor directs arginine methylation of histone H3 by CARM1. J Biol Chem 2004; 279: 54348-57.
153. Goo YH, Sohn YC, Kim DH, et al. Activating signal cointegrator 2 belongs to a novel steady-state complex that contains a subset of trithorax group proteins. Mol Cell Biol 2003; 23: 140-9.
154. Lee S, Roeder RG, Lee JW. Roles of histone H3-lysine 4 methyltransferase complexes in NR-mediated gene transcription. Prog Mol Biol Transl Sci 2009; 87: 343-82.
155. Kim DH, Lee J, Lee B, et al. ASCOM controls farnesoid X receptor transactivation through its associated histone H3 lysine 4 methyltransferase activity. Mol Endocrinol 2009; 23: 1556-62.
156. Ananthanarayanan M, Li Y, Surapureddi S, et al. Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G771-81.
157. Kim DH, Lee JW. Tumor suppressor p53 regulates bile acid homeostasis via small heterodimer partner. Proc Natl Acad Sci USA 2011; 108: 12266-70.
158. Lee J, Kim DH, Lee S, et al. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci USA 2009; 106: 8513-8.
159. Kim DH, Kim J, Lee JW. Requirement for MLL3 in p53 regulation of hepatic expression of small heterodimer partner and bile acid homeostasis. Mol Endocrinol 2011; 25: 2076-83.
160. Xia M, Xu L, Leng Y, et al. Downregulation of MLL3 in esophageal squamous cell carcinoma is required for the growth and metastasis of cancer cells. Tumour Biol 2015; 36: 605-13.
161. Li B, Liu HY, Guo SH, et al. Association of MLL3 expression with prognosis in gastric cancer. Genet Mol Res 2014; 13: 7513-8.
162. Watanabe Y, Castoro RJ, Kim HS, et al. Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One 2011; 6: e23320.
163. Stepanov V, Stankov K, Mikov M. The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res 2013; 33: 213-23.
164. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-9.
165. Macchiarulo A, Gioiello A, Thomas C, et al. Probing the binding site of bile acids in TGR5. ACS Med Chem Lett 2013; 4: 1158-62.
166. Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-93.
167. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-40.
168. Perino A, Schoonjans K. TGR5 and Immunometabolism: Insights from physiology and pharmacology. Trends Pharmacol Sci 2015; 36: 847-57.
169. Keitel V, Gorg B, Bidmon HJ, et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia 2010; 58: 1794-805.
170. Perino A, Pols TWH, Nomura M, et al. TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation. J Clin Invest 2014; 124: 5424-36.
171. Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009; 50: 861-70.
172. Li T, Holmstrom SR, Kir S, et al. The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 2011; 25: 1066-71.
173. Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut 2016; 65: 487-501.
174. Alemi F, Poole DP, Chiu J, et al. The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 2013; 144: 145-54.
175. Zhou H, Zhou S, Gao J, et al. Upregulation of bile acid receptor TGR5 and nNOS in gastric myenteric plexus is responsible for delayed gastric emptying after chronic high-fat feeding in rats. Am J Physiol Gastrointest Liver Physiol 2015; 308: G863-73.
176. Ward JB, Mroz MS, Keely SJ. The bile acid receptor, TGR5, regulates basal and cholinergic-induced secretory responses in rat colon. Neurogastroenterol Motil 2013; 25: 708-11.
177. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-9.
178. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-77.
179. Kumar DP, Rajagopal S, Mahavadi S, et al. Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells. Biochem Biophys Res Commun 2012; 427: 600-5.
180. Kumar DP, Asgharpour A, Mirshahi F, et al. Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet alpha cells to promote glucose homeostasis. J Biol Chem 2016; 291(13): 6626-40.
181. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011; 14: 747-57.
182. McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013; 288: 11761-70.
183. Fryer RM, Ng KJ, Nodop Mazurek SG, et al. G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism. J Pharmacol Exp Ther 2014; 348: 421-31.
184. Boesjes M, Brufau G. Metabolic effects of bile acids in the gut in health and disease. Curr Med Chem 2014; 21: 2822-9.
185. Everard A, Cani PD. Gut microbiota and GLP-1. Rev Endocr Metab Disord 2014; 15: 189-96.
186. Yadav H, Lee JH, Lloyd J, et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem 2013; 288: 25088-97.
187. Harach T, Pols TWH, Nomura M, et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Reports 2012; 2: 430.
188. Jimenez A, Mari A, Casamitjana R, et al. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes 2014; 63: 3372-7.
189. Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2014; 2: 152-64.
190. Raghow R. Menage-a-trois of bariatric surgery, bile acids and the gut microbiome. World J Diabetes 2015; 6: 367-70.
191. Jansen PL, van Werven J, Aarts E, et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis 2011; 29: 48-51.
192. Pellicciari R, Sato H, Gioiello A, et al. Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23-and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5. J Med Chem 2007; 50: 4265-8.
193. Pellicciari R, Gioiello A, Macchiarulo A, et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 2009; 52: 7958-61.
194. Sato H, Genet C, Strehle A, et al. Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea. Biochem Biophys Res Commun 2007; 362: 793-8.
195. Genet C, Strehle A, Schmidt C, et al. Structure-activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 2010; 53: 178-90.
196. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010; 138: 1102-11.
197. Hov JR, Keitel V, Laerdahl JK, et al. Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One 2010; 5: e12403.
198. Poole DP, Godfrey C, Cattaruzza F, et al. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol Motil 2010;22: 814-25.
199. Camilleri M, Vazquez-Roque MI, Carlson P, et al. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil 2011; 23: 995-9.
200. Camilleri M, Shin A, Busciglio I, et al. Genetic variation in GPBAR1 predisposes to quantitative changes in colonic transit and bile acid excretion. Am J Physiol Gastrointest Liver Physiol 2014; 307: G508-16.
201. Mussig K, Staiger H, Machicao F, et al. Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus. Metabolism 2009; 58: 1809-11.
202. Rose NR, Klose RJ. Understanding the relationship between DNA methylation and histone lysine methylation. Biochim Biophys Acta 2014; 1839: 1362-72.
203. Han LY, Fan YC, Mu NN, et al. Aberrant DNA methylation of Gprotein-coupled bile acid receptor gpbar1 (TGR5) is a potential biomarker for hepatitis B virus associated hepatocellular carcinoma. Int J Med Sci 2014; 11: 164-71.
204. Gao S, Ji XF, Li F, et al. Aberrant DNA methylation of G-proteincoupled bile acid receptor Gpbar1 predicts prognosis of acute-onchronic hepatitis B liver failure. J Viral Hepat 2015; 22: 112-9.
205. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998; 92: 73-82.
206. Krasowski MD, Yasuda K, Hagey LR, et al. Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Nucl Recept 2005; 3: 2.
207. Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: Genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 555-72.
208. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 1998; 95: 12208-13.
209. Lamba V, Yasuda K, Lamba JK, et al. PXR (NR1I2): Splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Tox Appl Pharmacol 2004; 199: 251-65.
210. Carnahan VE, Redinbo MR. Structure and function of the human nuclear xenobiotic receptor PXR. Curr Drug Metab 2005; 6: 357-67.
211. Koyano S, Kurose K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): One variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos 2004; 32: 149-54.
212. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr Rev 2002; 23: 687-702.
213. Zhang B, Xie W, Krasowski MD. PXR: A xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008; 9: 1695-709.
214. Gao L, He Y, Tang J, et al. Genetic variants of pregnane X receptor (PXR) and CYP2B6 affect the induction of bupropion hydroxylation by sodium ferulate. PLoS One 2013; 8: e62489.
215. Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000; 14: 27-39.
216. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23.
217. Hernandez JP, Mota LC, Baldwin WS. Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr Pharmacogenomics Person Med 2009; 7: 81-105.
218. Rosenfeld JM, Vargas Jr R, Xie W, et al. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane x receptor. Mol Endocrinol 2003; 17: 1268-82.
219. Olinga P, Elferink MGL, Draaisma AL, et al. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 2008; 33: 380-9.
220. Moore LB, Goodwin B, Jones SA, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 7500-2.
221. Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002; 1: 259-66.
222. He K, Woolf TF, Kindt EK, Fielder AE, et al.Troglitazone quinone formation catalyzed by human and rat CYP3A: An atypical CYP oxidation reaction. Biochem Pharmacol 2001; 62: 191-8.
223. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001; 7: 584-90.
224. Mani S, Dou W, Redinbo MR. PXR antagonists and implication in drug metabolism. Drug Metab Rev 2013; 45: 60-72.
225. Ekins S, Kholodovych V, Ai N, et al. Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 2008; 74: 662-72.
226. Jonker JW, Liddle C, Downes M. FXR and PXR: Potential therapeutic targets in cholestasis. J Steroid Biochem Mol Biol 2012; 130: 147-58.
227. Saini SPS, Mu Y, Gong H, et al. Dual role of orphan nuclear receptor pregnane X receptor in bilirubin detoxification in mice. Hepatology 2005; 41: 497-505.
228. Gao J, Xie W. Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci 2012; 33: 552-8.
229. Kodama S, Koike C, Negishi M, et al. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drugmetabolizing and gluconeogenic enzymes. Mol Cell Biol 2004; 24: 7931-40.
230. Bhalla S, Ozalp C, Fang S, et al. Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1α. Functional implications in hepatic cholesterol and glucose metabolism. J Biol Chem 2004; 279: 45139-47.
231. Ma Y, Liu D. Activation of pregnane X receptor by pregnenolone 16 α-carbonitrile prevents high-fat diet-induced obesity in AKR/J mice. PLoS One 2012; 7: e38734.
232. Hukkanen J, Hakkola J, Rysa J. Pregnane X receptor (PXR)-A contributor to the diabetes epidemic? Drug Metabol Drug Interact 2014; 29: 3-15.
233. Wada T, Gao J, Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab 2009; 20: 273-9.
234. Zhou J, Zhai Y, Mu Y, et al. A novel pregnane X receptormediated and sterol regulatory element-binding proteinindependent lipogenic pathway. J Biol Chem 2006; 281: 15013-20.
235. Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARγ in promoting steatosis. Gastroenterology 2008; 134: 556-67.
236. Zhou C, King N, Chen KY, et al. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J Lipid Res 2009; 50: 2004-13.
237. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-67.
238. Martinez A, Marquez A, Mendoza J, et al. Role of the PXR gene locus in inflammatory bowel diseases. Inflamm Bowel Dis 2007; 13: 1484-7.
239. Xie W, Tian Y. Xenobiotic receptor meets NF-κB, a collision in the small bowel. Cell Metab 2006; 4: 177-8.
240. Cheng J, Shah YM, Gonzalez FJ. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci 2012; 33: 323-30.
241. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115: 177-86.
242. Shizu R, Benoki S, Numakura Y, et al. Xenobiotic-Induced Hepatocyte Proliferation Associated with Constitutive Active/ Androstane Receptor (CAR) or Peroxisome Proliferator-Activated Receptor α (PPARα) Is Enhanced by Pregnane X Receptor (PXR) Activation in Mice. PLoS One 2013; 8: e61802.
243. Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: Solving the puzzle with nuclear receptors. Trends Mol Med 2011; 17: 564-72.
244. Teng S, Piquette-Miller M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J Pharmacol Exp Ther 2005; 312: 841-8.
245. Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA 2001; 98: 3369-74.
246. Woolbright BL, Dorko K, Antoine DJ, et al. Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis. Toxicol Appl Pharmacol 2015; 283: 168-77.
247. Cynamon HA, Andres JM, Iafrate RP. Rifampin relieves pruritus in children with cholestatic liver disease. Gastroenterology 1990; 98: 1013-6.
248. Bachs L, Pares A, Elena M, et al. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102: 2077-80.
249. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005; 129: 476-85.
250. Kotta-Loizou I, Patsouris E, Theocharis S. Pregnane X receptor polymorphisms associated with human diseases. Expert Opin Ther Targets 2013; 17: 1167-77.
251. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: Dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 26-40.
252. Dring MM, Goulding CA, Trimble VI, et al. The Pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 2006; 130: 341-8.
253. Ho GT, Soranzo N, Tate SK, et al. Lack of association of the pregnane X receptor (PXR/NR112) gene with inflammatory bowel disease: Parallel allelic association study and gene wide haplotype analysis. Gut 2006; 55: 1676-7.
254. Andersen V, Christensen J, Ernst A, et al. Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of infammatory bowel disease. World J Gastroenterol 2011; 17: 197-206.
255. Glas J, Seiderer J, Fischer D, et al. Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1917-24.
256. Sookoian S, Castano GO, Burgueno AL, et al. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics 2010; 20: 1-8.
257. Van de Winkel A, Menke V, Capello A, et al. Expression, localization and polymorphisms of the nuclear receptor PXR in Barrett's esophagus and esophageal adenocarcinoma. BMC Gastroenterol 2011; 11: 108
258. Owen BM, Van Mil SWC, Boudjelal M, et al. Sequencing and functional assessment of hPXR (NR1I2) variants in intrahepatic cholestasis of pregnancy. Xenobiotica 2008; 38: 1289-97.
259. Castano G, Burgueno A, Fernandez Gianotti T, et al. The influence of common gene variants of the xenobiotic receptor (PXR) in genetic susceptibility to intrahepatic cholestasis of pregnancy. Aliment Pharmacol Ther 2010; 31: 583-92.
260. Karlsen TH, Lie BA, Frey Froslie K, et al. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 2006; 131: 781-87.
261. Folwaczny M, Tengler B, Glas J. Variants of the human NR1I2 (PXR) locus in chronic periodontitis. J Periodont Res 2012; 47: 174-9.
262. Wang YM, Chai SC, Brewer CT, et al. Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol 2014; 10: 1521-32.
263. Andrews E, Armstrong M, Tugwood J, et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 2010; 51: 1656-64.
264. Andersen V, Christensen J, Overvad K, et al. Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer 2010; 10: 484.
265. Justenhoven C, Schaeffeler E, Winter S, et al. Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk. Breast Cancer Res Treat 2011; 125: 563-9.
266. Zhang L, Qiu F, Lu X, et al. A functional polymorphism in the 3'-UTR of PXR Interacts with smoking to increase lung cancer risk in Southern and Eastern Chinese smoker. Int J Mol Sci 2014; 15: 17457-68.
267. Reyes-Hernandez OD, Vega L, Jimenez-Rios MA, et al. The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients. PLoS One 2014; 9: e99974.
268. Campa D, Butterbach K, Slager SL, et al. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk. Int J Cancer 2012; 131: 803-12.
269. Martino A, Sainz J, Reis RM, et al. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: A case-control study in the context of the IMMEnSE consortium. J Hum Genet 2013; 58: 155-9.
270. Hustert E, Zibat A, Presecan-Siedel E, et al. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001; 29: 1454-9.
271. Oleson L, Von Moltke LL, Greenblatt DJ, et al. Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica 2010; 40: 146-62.
272. Du QQ, Wang ZJ, He L, et al. PXR polymorphisms and their impact on pharmacokinetics/pharmacodynamics of repaglinide in healthy Chinese volunteers. Eur J Clin Pharmacol. 2013; 69: 1917-25.
273. Noetzli M, Guidi M, Ebbing K, et al. Population pharmacokinetic study of memantine: Effects of clinical and genetic factors. Clin Pharmacokinetics 2013; 52: 211-23.
274. Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 2008; 8: 139-46.
275. Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: Association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 2008; 14: 7116-26.
276. Siccardi M, D'Avolio A, Baietto L, et al. Association of a singlenucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008; 47: 1222-5.
277. D'Avolio A, Carcieri C, Cusato J, et al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother 2014; 69: 3061-6.
278. Tian Y. Epigenetic regulation of pregnane X receptor activity. Drug Metab Rev 2013; 45: 166-72.
279. Tang Q, Chen Y, Meyer C, et al. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res 2011; 71: 6940-7.
280. Orans J, Teotico DG, Redinbo MR. The nuclear xenobiotic receptor pregnane X receptor: Recent insights and new challenges. Mol Endocrinol 2005; 19: 2891-900.
281. Ma X, Chen J, Tian Y. Pregnane X receptor as the sensor and effector in regulating epigenome. J Cell Physiol 2015; 230: 752-7.
282. Garber M, Yosef N, Goren A, et al. A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals. Mol Cell 2012; 47: 810-22.
283. Cui JY, Gunewardena SS, Rockwell CE, et al. ChIPing the cistrome of PXR in mouse liver. Nucleic Acids Res 2010; 38: 7943-63.
284. Breuker C, Planque C, Rajabi F, et al. Characterization of a novel PXR isoform with potential dominant-negative properties. J Hepatol 2014; 61: 609-16.
285. Tirona RG, Lee W, Leake BF, et al. The orphan nuclear receptor HNF4α determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003; 9: 220-4.
286. Takagi S, Nakajima M, Mohri T, et al. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 2008; 283: 9674-80.
287. Cabrerizo R, Castano GO, Burgueno AL, et al. Promoter DNA methylation of farnesoid X receptor and pregnane X receptor modulates the intrahepatic cholestasis of pregnancy phenotype. PLoS One 2014; 9: e87697.
288. Habano W, Gamo T, Terashima J, et al. Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer 2011; 11: 81.
289. Venkatesh M, Mukherjee S, Wang H, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and toll-like receptor 4. Immunity 2014; 41: 296-310.
290. Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009; 106: 4402-7.
291. Velenosi TJ, Feere DA, Sohi G, et al. Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease. FASEB J 2014; 28: 5388-97.
292. Omiecinski CJ, Coslo DM, Chen T, et al. Multi-species analyses of direct activators of the constitutive androstane receptor. Toxicol Sci 2011; 123: 550-62.
293. Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-β. Nature 1998; 395: 612-615.
294. Jinno H, Tanaka-Kagawa T, Hanioka N, et al. Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. Mol Pharmacol 2004; 65: 496-502.
295. Lamba JK. Pharmacogenetics of the constitutive androstane receptor. Pharmacogenomics 2008; 9: 71-83.
296. Kachaylo EM, Pustylnyak VO, Lyakhovich VV, et al. Constitutive androstane receptor (CAR) is a xenosensor and target for therapy. Biochemistry (Mosc) 2011; 76: 1087-97.
297. Suino K, Peng L, Reynolds R, et al. The nuclear xenobiotic receptor CAR: Structural determinants of constitutive activation and heterodimerization. Mol Cell 2004; 16: 893-905.
298. Molnar F, Kublbeck J, Jyrkkarinne J, et al. An update on the constitutive androstane receptor (CAR). Drug Metab Drug Interact 2013; 28: 79-93.
299. Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 2000; 275: 15122-7.
300. Kobayashi K, Hashimoto M, Honkakoski P, et al. Regulation of gene expression by CAR: an update. Arch Toxicol 2015; 89: 1045-55.
301. Moore LB, Maglich JM, McKee DD, et al. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002; 16: 977-86.
302. Mutoh S, Osabe M, Inoue K, et al. Dephosphorylation of threonine 38 Is required for nuclear translocation and activation of human xenobiotic receptor CAR (NR1I3). J Biol Chem 2009; 284: 34785-92.
303. Yang H, Garzel B, Heyward S, et al. Metformin represses druginduced expression of cyp2b6 by modulating the constitutive androstane receptor signalings. Mol Pharmacol 2014; 85: 249-60.
304. Sueyoshi T, Moore R, Sugatani J, et al. PPP1R16A, the membrane subunit of protein phosphatase 1β, signals nuclear translocation of the nuclear receptor constitutive active/androstane receptor. Mol Pharmacol 2008; 73: 1113-21.
305. Mutoh S, Sobhany M, Moore R, et al. Phenobarbital indirectly activates the constitutive active androstane receptor (car) by inhibition of epidermal growth factor receptor signaling. Sci Signal 2013; 6: ra31.
306. Sueyoshi T, Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 2001; 41: 123-43.
307. Maglich JM, Stoltz CM, Goodwin B, et al. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 2002; 62: 638-46.
308. Wang X, Sykes DB, Miller DS. Constitutive androstane receptormediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol 2010; 78: 376-83.
309. Zhang J, Huang W, Chua SS, et al. Modulation of acetaminopheninduced hepatotoxicity by the xenobiotic receptor CAR. Science 2002; 298: 422-4.
310. Wei P, Zhang J, Egan-Haftey M, et al. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000; 407: 920-3.
311. Chen X, Meng Z, Wang X, et al. The nuclear receptor CAR modulates alcohol-induced liver injury. Lab Invest 2011; 91: 1136-45.
312. Zhang XJ, Shi Z, Lyv JX, et al. Pyrene is a novel constitutive androstane receptor (CAR) activator and causes hepatotoxicity by CAR. Toxicol Sci 2015; 147: 436-45
313. Li L, Chen T, Stanton JD, et al. The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinolinecarboxamide is a novel antagonist of human constitutive androstane receptor. Mol Pharmacol 2008; 74: 443-53.
314. Chang TKH. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J 2009; 11: 590-601.
315. Fan L, Wang G, Wang LS, et al. Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. Acta Pharmacol Sin 2007; 28: 1685-92.
316. Miao J, Fang S, Bae Y, et al. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1α. J Biol Chem 2006; 281: 14537-46.
317. Gao J, He J, Zhai Y, et al. The constitutive androstane receptor is an anti-obesity nuclear receptor that improves in sulin sensitivity. J Biol Chem 2009; 284: 25984-92.
318. Režen T, Tamasi V, Lovgren-Sandblom A, et al. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse livers. BMC Genomics 2009; 10: 384.
319. Sberna AL, Assem M, Xiao R, et al. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptordeficient mice. Arterioscler Thromb Vasc Biol 2011; 31: 2232-9.
320. Roth A, Looser R, Kaufmann M, et al. Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol Pharmacol 2008; 73: 1282-9.
321. Korhonen T, Uusitupa M, Voutilainen E, et al. Lack of effect of hepatic enzyme induction on metabolic control in patients with type 2 (non-insulin-dependent) diabetes. Clin Pharmacol Ther 1987; 41: 633-8.
322. Ueda A, Hamadeh HK, Webb HK, et al. Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002; 61: 1-6.
323. Gao J, Xie W. Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metab Dispos 2010; 38: 2091-5.
324. Maglich JM, Watson J, McMillen PJ, et al. The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem 2004; 279: 19832-8.
325. Tien ES, Matsui K, Moore R, et al. The nuclear receptor constitutively active/androstane receptor regulates type 1 deiodinase and thyroid hormone activity in the regenerating mouse liver. J Pharmacol Exp Ther 2007; 320: 307-13.
326. Min G, Kim Kemper J, Kemper B. Glucocorticoid receptorinteracting protein 1 mediates ligand-independent nuclear translocation and activation of constitutive androstane receptor in vivo. J Biol Chem 2002; 277: 26356-63.
327. Yamamoto Y, Moore R, Goldsworthy TL, et al. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res 2004; 64: 7197-200.
328. Braeuning A, Gavrilov A, Brown S, et al. Phenobarbital-mediated tumor promotion in transgenic mice with humanized CAR and PXR. Toxicol Sci 2014; 140: 259-70.
329. Moennikes O, Buchmann A, Romualdi A, et al. Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in Connexin32-null mice. Cancer Res 2000; 60: 5087-91.
330. Yamamoto Y, Negishi M. The antiapoptotic factor growth arrest and DNA-damage-inducible 45 β regulates the nuclear receptor constitutive active/androstane receptor-mediated transcription. Drug Metab Dispos 2008; 36: 1189-93.
331. Ledda-Columbano GM, Pibiri M, Cossu C, et al. Aging does not reduce the hepatocyte proliferative response of mice to the primary mitogen TCPOBOP. Hepatology 2004; 40: 981-8.
332. Stedman C, Robertson G, Coulter S, et al. Feed-forward regulation of bile acid detoxification by CYP3A4: Studies in humanized transgenic mice. J Biol Chem 2004; 279: 11336-43.
333. Li T, Chiang JYL. Nuclear receptors in bile acid metabolism. Drug Metab Rev 2013; 45: 145-55.
334. Wagner M, Halilbasic E, Marschall HU, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005; 42: 420-30.
335. Saini SPS, Sonoda J, Xu L, et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol Pharmacol 2004; 65: 292-300.
336. Uppal H, Toma D, Saini SPS, et al. Combined loss of orphan receptor PXR and CAR heightens sensitivity to toxic bile acids in mice. Hepatology 2005; 41: 168-76.
337. Stedman CAM, Liddle C, Coulter SA, et al. Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci USA 2005; 102: 2063-8.
338. Beilke LD, Aleksunes LM, Holland RD, et al. Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-Induced liver injury in mice. Drug Metab Dispos 2009; 37: 1035-45.
339. Wortham M, Czerwinski M, He L, et al. Expression of constitutive androstane receptor, hepatic nuclear factor 4α, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 2007; 35: 1700-10.
340. Betts S, Bjorkhem-Bergman L, Rane A, et al. Expression of CYP3A4 and CYP3A7 in human foetal tissues and its correlation with nuclear receptors. Basic Clin Pharmacol Toxicol 2015; 117: 261-6.
341. Swart M, Whitehorn H, Ren Y, et al. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med Genet 2012; 13: 112.
342. Wyen C, Hendra H, Siccardi M, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenzcontaining regimens. J Antimicrob Chemother 2011; 66: 2092-8.
343. Olagunju A, Siccardi M, Amara A, et al. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a serbian cohort of HIV patients. Ther Drug Monit 2014; 36: 734-8.
344. Van Der Veldt AAM, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res. 2011; 17: 620-9.
345. Narjoz C, Cessot A, Thomas-Schoemann A, et al. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs 2015; 33: 257-68.
346. Chen D, Guo F, Shi J, et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients. Drug Metab Pharmacokinet 2014; 29: 249-53.
347. Zang M, Zhao L, Zhu F, et al. Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects. Drug Metab Pharmacokinet 2015; 30: 123-6.
348. Lima LO, Bruxel EM, Hutz MH, et al. Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipidlowering efficacy and safety of statin therapy. Arq Bras Endocrinol Metabol 2013; 57: 513-9.
349. Da Rosa JCF, Fiegenbaum M, Soledar AL, et al. Cytogenetic evaluation and the association with polymorphisms of the CPY1A1 and NR1I3 genes in individuals exposed to BTEX. Environ Monit Assess 2013; 185: 5883-90.
350. Gaulton KJ, Wilier CJ, Li Y, et al. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes. Diabetes 2008; 57: 3136-44.
351. Urano T, Usui T, Shiraki M, et al. Association of a single nucleotide polymorphism in the constitutive androstane receptor gene with bone mineral density. Geriatr Gerontol Int 2009; 9: 235-41.
352. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999; 20: 321-44.
353. Ohno M, Kanayama T, Moore R, et al. The roles of co-chaperone CCRP/DNAJC7 in Cyp2b10 gene activation and steatosis development in mouse livers. PLoS One 2014; 9: e115663.
354. Auerbach SS, Ramsden R, Stoner MA, et al. Alternatively spliced isoforms of the human constitutive androstane receptor. Nucleic Acids Res 2003; 31: 3194-07.
355. Takwi AA, Wang YM, Wu J, et al. miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene 2014; 33: 3717-29.
356. Takizawa D, Kakizaki S, Horiguchi N, et al. Histone deacetylase inhibitors induce cytochrome P450 2B by activating nuclear receptor constitutive androstane receptor. Drug Metab Dispos 2010; 38: 1493-8.
357. Lempiainen H, Muller A, Brasa S, et al. Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. PLoS One 2011; 6: e18216.
358. Chen WD, Fu X, Dong B, et al. Neonatal activation of the nuclear receptor CAR results in epigenetic memory and permanent change of drug metabolism in mouse liver. Hepatology 2012; 56: 1499-508.
359. Ince I, Knibbe CAJ, Danhof M, et al. Developmental changes in the expression and function of cytochrome p450 3a isoforms: Evidence from in vitro and in vivo investigations. Clin Pharm 2013; 52: 333-45.
360. Phillips JM, Yamamoto Y, Negishi M, et al. Orphan nuclear receptor constitutive active/androstane receptor-mediated alterations in DNA methylation during phenobarbital promotion of liver tumorigenesis. Toxicol Sci 2007; 96: 72-82.
361. Thomson JP, Moggs JG, Wolf CR, et al. Epigenetic profiles as defined signatures of xenobiotic exposure. Mutat Res Genet Toxicol Environ Mutagen 2014; 764-765: 3-9.
362. Tian J, Locker J. Gadd45 in the liver: signal transduction and transcriptional mechanisms. Adv Exp Med Biol 2013; 793: 69-80.
363. Lempiainen H, Couttet P, Bolognani F, et al. Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion. Toxicol Sci 2013; 131: 375-86.
364. Chen S, He N, Yu J, et al. Post-transcriptional regulation by miR-137 underlies the low abundance of CAR and low rate of bilirubin clearance in neonatal mice. Life Sci 2014; 107: 8-13.
365. Masuyama H, Hiramatsu Y. Treatment with constitutive androstane receptor ligand during pregnancy prevents insulin resistance in offspring from high-fat diet-induced obese pregnant mice. Am J Physiol Endocrinol Metab 2012; 303: E293-300.